Limeng Wu

机构：Shenyang Pharmaceutical University, General Hospital of Shenyang Military Region

发表论文 27 篇 · 总被引 304 次 · h-index 11

代表论文

• Design, synthesis and biological evaluation of novel coumarin derivatives as multifunctional ligands for the treatment of Alzheimer's disease (2022 · European Journal of Medicinal Chemistry · 被引 48)
• An inhibitor with GSK3β and DYRK1A dual inhibitory properties reduces Tau hyperphosphorylation and ameliorates disease in models of Alzheimer's disease (2023 · Neuropharmacology · 被引 29)
• Discovery of novel β-carboline-1,2,3-triazole hybrids as AChE/GSK-3β dual inhibitors for Alzheimer's disease treatment (2022 · Bioorganic Chemistry · 被引 27)
• Design, synthesis, and biological evaluation of β-carboline 1,3,4-oxadiazole based hybrids as HDAC inhibitors with potential antitumor effects (2022 · Bioorganic & Medicinal Chemistry Letters · 被引 22)
• Discovery of novel harmine derivatives as GSK‐3β/DYRK1A dual inhibitors for Alzheimer's disease treatment (2023 · Archiv der Pharmazie · 被引 21)
• TRPM8 and TRPA1 ideal targets for treating cold-induced pain (2024 · European Journal of Medicinal Chemistry · 被引 16)